Z
4.72
0.14 (3.06%)
| Previous Close | 4.58 |
| Open | 4.69 |
| Volume | 226,869 |
| Avg. Volume (3M) | 434,595 |
| Market Cap | 308,185,312 |
| Price / Earnings (TTM) | 8.28 |
| Price / Book | 0.970 |
| 52 Weeks Range | |
| Earnings Date | 7 Nov 2024 |
| Diluted EPS (TTM) | -0.390 |
| Current Ratio (MRQ) | 10.36 |
| Operating Cash Flow (TTM) | -21.30 M |
| Levered Free Cash Flow (TTM) | -18.87 M |
| Return on Assets (TTM) | -21.40% |
| Return on Equity (TTM) | -36.85% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Zura Bio Limited | Bearish | Bullish |
AIStockmoo Score
-1.6
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | -4.5 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -2.5 |
| Average | -1.63 |
|
Zura Bio Ltd is a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 31.87% |
| % Held by Institutions | 58.01% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 15.00 (Leerink Partners, 217.80%) | Buy |
| Median | 12.00 (154.24%) | |
| Low | 5.00 (HC Wainwright & Co., 5.93%) | Hold |
| Average | 10.67 (126.06%) | |
| Total | 2 Buy, 1 Hold | |
| Avg. Price @ Call | 3.75 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 24 Dec 2024 | 5.00 (5.93%) | Hold | 2.31 |
| 18 Nov 2024 | 5.00 (5.93%) | Hold | 3.21 | |
| Chardan Capital | 08 Nov 2024 | 12.00 (154.24%) | Buy | 4.58 |
| Leerink Partners | 04 Nov 2024 | 15.00 (217.80%) | Buy | 4.37 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 23 Dec 2024 | Announcement | Zura Bio Launches Global Phase 2 TibuSURE Study to Evaluate Tibulizumab in Adults With Systemic Sclerosis |
| 25 Nov 2024 | Announcement | Zura Bio to Present at the Piper Sandler 36th Annual Healthcare Conference |
| 14 Nov 2024 | Announcement | Zura Bio Announces Submission of Protocol to U.S. Food and Drug Administration for the Phase 2 Study of Tibulizumab in Adults with Systemic Sclerosis |
| 07 Nov 2024 | Announcement | Zura Bio Reports Third Quarter 2024 Financial Results and Recent Corporate Updates |
| 30 Oct 2024 | Announcement | Zura Bio to Participate in Two Upcoming Investor Conferences in November |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |